AZ pitches social-media rules to FDA

AstraZeneca has made its social-media pitch to the FDA. In response to the agency's call for comments on new rules for online marketing and communications, the drugmaker outlined some ways interactions with customers--and potential customers--might be governed.

The drugmaker's entire submission is online, so for all the details, you'll want to read it. But we'd like to highlight one of the overarching themes: That certain online communications, such as Facebook and Twitter posts, should be judged not one by one, but as a mosaic of individual comments. That, of course, would enable drugmakers to participate in those sorts of social-media sites without having to balance benefits and risks at every 140-character turn. The balance would be more big-picture than piecemeal.

Another theme: The distinctions between the content on websites a drugmaker owns and controls--such as a brand site set up and hosted by the company--versus sites where it provides content for sponsors to use as they see fit. And then there are the social-media sites, which would include real-time company communications. All of which are distinct from independent commentary that a company has no control over. Different rules should apply in different contexts, AZ suggests.

How the FDA might view these suggestions is anybody's guess; the agency is starting from Square One on this social-media-oversight thing. But what do you pharma-marketing types think of AZ's arguments?

- read the AZ submission
- check out the press release

Virtual Clinical Trials Summit

Virtual Clinical Trials Summit: The Premier Educational Event Focused on Decentralized Clinical Trials

In this virtual environment, we will look at current and future trends for ongoing virtual trials, diving into the many ways companies can improve patient engagement and trial behavior to enhance retention with a focus on emerging technology and harmonized data access across the clinical trial system.